IN2012DN01964A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01964A IN2012DN01964A IN1964DEN2012A IN2012DN01964A IN 2012DN01964 A IN2012DN01964 A IN 2012DN01964A IN 1964DEN2012 A IN1964DEN2012 A IN 1964DEN2012A IN 2012DN01964 A IN2012DN01964 A IN 2012DN01964A
- Authority
- IN
- India
- Prior art keywords
- metformin
- amount
- disclosed
- subject
- chemotherapeutic agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed herein is a method for treating a tumor in a subject in need thereof comprising administering an enhancing amount of metformin and a reduced amount of one or more chemotherapeutic agents. One example of an enhancing amount of metformin is about 250 mg/day. Also disclosed is a method for preventing cancer or delaying the recurrence of cancer in a subject comprising administering an effective amount of metformin to the subject. In one example of such a method, the amount of metformin is about 75 mg/day. Also disclosed is a composition comprising an enhancing amount of metformin, and a reduced amount of one or more chemotherapeutic agents and a pharmaceutically acceptable carrier. Kits comprising metformin and one or more chemotherapeutic agents are also disclosed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23677809P | 2009-08-25 | 2009-08-25 | |
PCT/US2010/046616 WO2011031474A2 (en) | 2009-08-25 | 2010-08-25 | Use of metformin in cancer treatment and prevention |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN01964A true IN2012DN01964A (en) | 2015-08-21 |
Family
ID=43733025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1964DEN2012 IN2012DN01964A (en) | 2009-08-25 | 2010-08-25 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20120220664A1 (en) |
EP (1) | EP2470170A4 (en) |
JP (1) | JP2013503171A (en) |
KR (1) | KR20120080579A (en) |
CN (1) | CN102596192A (en) |
AU (1) | AU2010292599A1 (en) |
BR (1) | BR112012004281A2 (en) |
CA (1) | CA2772120A1 (en) |
IL (1) | IL218287A0 (en) |
IN (1) | IN2012DN01964A (en) |
MX (1) | MX2012002337A (en) |
SG (1) | SG178556A1 (en) |
WO (1) | WO2011031474A2 (en) |
ZA (1) | ZA201201434B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011084523A2 (en) * | 2009-12-15 | 2011-07-14 | The Salk Institute For Biological Studies | Ulk1 compositions, inhibitors, screening and methods of use |
CN103347521B (en) * | 2010-12-06 | 2018-05-25 | 全球癌症治疗有限责任公司 | Chemotherapy and the method for the metabolism target cancer cell of immunization therapy are used for treating cancer |
US9532984B2 (en) * | 2011-06-10 | 2017-01-03 | The Translational Genomics Research Institute | Therapeutic combination for cancer treatment |
CN102327256B (en) * | 2011-09-22 | 2014-01-29 | 上海交通大学医学院附属瑞金医院 | Application of dimethyldiguanide in preparation of medicaments for treating lymphoma diseases |
WO2013086002A1 (en) * | 2011-12-05 | 2013-06-13 | Cellworks Research India Private Limited | Compositions, process of preparation of said compositions and method of treating cancer |
US9622982B2 (en) * | 2013-01-14 | 2017-04-18 | Health Clinics Limited | Cancer drug and uses |
AU2014250795B2 (en) * | 2013-04-12 | 2019-07-18 | Ned Biosystems, Inc. | Cancer therapy |
JP6242071B2 (en) * | 2013-04-23 | 2017-12-06 | 国立大学法人 岡山大学 | Immune exhausted CD8 + T cell function improving agent, cancer therapeutic agent and preventive or therapeutic agent for metabolic syndrome |
TWI688387B (en) | 2013-05-24 | 2020-03-21 | 日商加齡 營養研究所股份有限公司 | Pharmaceutial uses of dihydroquercetin or a pharmaceutically acceptable salt thereof or combinations containing the same |
WO2015183794A1 (en) | 2014-05-27 | 2015-12-03 | City Of Hope | Tgr5 agonist complexes for treating diabetes and cancer |
WO2016025725A1 (en) * | 2014-08-14 | 2016-02-18 | The Medical College Of Wisconsin, Inc. | Modified mito-metformin compounds and methods of synthesis and use thereof |
AU2015304448B2 (en) * | 2014-08-19 | 2020-04-30 | National University Corporation Okayama University | Method for enhancing immune cell function and method for assessing immune cell multifunctionality |
WO2016026933A1 (en) * | 2014-08-21 | 2016-02-25 | Centre National De La Recherche Scientifique - Cnrs - | Adjuvant or neoadjuvant therapy for sensitizing cancer stem cells to chemotherapy |
SG10202007867PA (en) * | 2016-02-16 | 2020-09-29 | Agency Science Tech & Res | Cancer epigenetic profiling |
CA3059210C (en) | 2016-05-19 | 2022-07-19 | The Regents Of The University Of California | Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer |
CN106727468A (en) * | 2017-04-01 | 2017-05-31 | 四川大学 | The application and pharmaceutical composition of melbine and joint melbine and vincristine in treatment leukemia medicament is prepared |
EP3612187B1 (en) | 2017-04-21 | 2022-04-13 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
US11229657B2 (en) | 2017-04-21 | 2022-01-25 | Lunella Biotech, Inc. | Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy |
EP3624840A4 (en) | 2017-05-19 | 2021-03-10 | Lunella Biotech, Inc. | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
EP3624897A4 (en) | 2017-05-19 | 2021-07-14 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
WO2019183003A1 (en) * | 2018-03-18 | 2019-09-26 | The University Of North Carolina At Chapel Hill | Methods and assays for endometrial diseases |
CN117338938A (en) * | 2019-02-28 | 2024-01-05 | 北京强新生物科技有限公司 | Combination therapy for the treatment of central nervous system disorders |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006031931A2 (en) * | 2004-09-15 | 2006-03-23 | The President And Fellows Of Harvard College | Reducing er stress in the treatment of obesity and diabetes |
US7465804B2 (en) * | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
DE102006026026A1 (en) * | 2006-06-01 | 2007-12-06 | Grünenthal GmbH | drug |
US20080188457A1 (en) * | 2007-02-02 | 2008-08-07 | Braincells, Inc. | Modulation of Neurogenesis with Biguanides and GSK3-beta Agents |
WO2008110491A2 (en) * | 2007-03-09 | 2008-09-18 | University Of Basel | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat |
WO2009101199A2 (en) * | 2008-02-15 | 2009-08-20 | Bodo Melnik | Treatment of acne vulgaris; rosacea and rhinophym |
-
2010
- 2010-08-25 BR BR112012004281A patent/BR112012004281A2/en not_active Application Discontinuation
- 2010-08-25 CA CA2772120A patent/CA2772120A1/en not_active Abandoned
- 2010-08-25 JP JP2012526936A patent/JP2013503171A/en active Pending
- 2010-08-25 AU AU2010292599A patent/AU2010292599A1/en not_active Abandoned
- 2010-08-25 WO PCT/US2010/046616 patent/WO2011031474A2/en active Application Filing
- 2010-08-25 US US13/391,890 patent/US20120220664A1/en not_active Abandoned
- 2010-08-25 KR KR1020127007261A patent/KR20120080579A/en not_active Application Discontinuation
- 2010-08-25 EP EP10815838A patent/EP2470170A4/en not_active Withdrawn
- 2010-08-25 MX MX2012002337A patent/MX2012002337A/en not_active Application Discontinuation
- 2010-08-25 SG SG2012013017A patent/SG178556A1/en unknown
- 2010-08-25 IN IN1964DEN2012 patent/IN2012DN01964A/en unknown
- 2010-08-25 CN CN2010800480600A patent/CN102596192A/en active Pending
-
2012
- 2012-02-23 IL IL218287A patent/IL218287A0/en unknown
- 2012-02-27 ZA ZA2012/01434A patent/ZA201201434B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20120080579A (en) | 2012-07-17 |
ZA201201434B (en) | 2013-05-29 |
EP2470170A4 (en) | 2013-01-02 |
JP2013503171A (en) | 2013-01-31 |
WO2011031474A2 (en) | 2011-03-17 |
BR112012004281A2 (en) | 2016-03-08 |
CA2772120A1 (en) | 2011-03-17 |
AU2010292599A1 (en) | 2012-03-15 |
IL218287A0 (en) | 2012-04-30 |
EP2470170A2 (en) | 2012-07-04 |
CN102596192A (en) | 2012-07-18 |
US20120220664A1 (en) | 2012-08-30 |
MX2012002337A (en) | 2012-06-25 |
WO2011031474A3 (en) | 2011-06-16 |
SG178556A1 (en) | 2012-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN01964A (en) | ||
IL258880A (en) | Diarylhydantoin compounds | |
TW200621240A (en) | Cancer treatments | |
MX365138B (en) | Prolyl hydroxylase inhibitors. | |
MX2007009649A (en) | Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer. | |
HK1139863A1 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha | |
WO2011056021A3 (en) | Use of benzo-heterocycle derivatives for preventing and treating cancer or for inhibiting cancer metastasis | |
PH12014501639A1 (en) | Pharmaceutical compositions and methods | |
MX2013010770A (en) | Treatment of solid tumours. | |
MY169330A (en) | Method for inhibition of deubiquitinating activity | |
SG163595A1 (en) | Use of tocotrienol composition for the prevention of cancer | |
WO2009105217A3 (en) | Complement inhibitors as therapeutic agents for treatment of cancer | |
PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
WO2006060819A3 (en) | Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells | |
EA200601471A1 (en) | CELL CELL PROLIFERATION INHIBITORS (OPTIONS), PHARMACEUTICAL COMPOSITION ON THEIR BASIS, METHOD OF DESTROYING CANCER CELLS (VARIANTS) AND METHOD OF TREATMENT AND PREVENTION OF MALANCES AND PREVENTION OF HUMAN MEDICINES | |
MX2012005849A (en) | Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells. | |
WO2009158526A3 (en) | Methods of reducing cellular proliferation by inhibiting acsvl3 | |
EP1547596A4 (en) | Medicinal composition and method for treating malignant tumor and utilization thereof | |
EA200970418A1 (en) | APPLICATION OF MULTITARGETIC KINAZ INHIBITOR FOR THE TREATMENT OR PREVENTION OF BRAIN CANCER | |
NZ604127A (en) | Neuroendocrine tumor treatment using mtor inhibitors | |
WO2006085033A3 (en) | Pharmaceutical compositions for the treatment of prostate cancer | |
MXNL05000001A (en) | Conjugates of carbohydrate-somatostatin-14. | |
UA101610C2 (en) | Nanoparticles comprising rapamycin and albumin as anticancer agent |